BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)

BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $61.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).

The analyst comments "2025 is shaping up to be a potentially transformative year for BMY shares, with several high-impact catalysts expected the balance of 2025. In this preview we outline our expectations for: ARISE in adjunctive schizophrenia (2Q25), Odyssey-HCM in nHCM (2Q25) and ADEPT-2 in Alzheimer's psychosis (2H25). We're warming up to the potential of the Bristol story, but need more clarity on how the current late-stage pipeline can return the P&L to consistent growth following the LOEs of Revlimid (almost done), Eliquis (up next), and Opdivo (end of the decade)."

For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.

Shares of Bristol-Myers Squibb Co. closed at $57.82 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• 3M Co. (MMM) Declares $0.78 Quarterly Dividend; 1.7% Yield
• Active options: TSLA NVDA SPCX MU AAPL AMD INTC AMZN